

Consolidated Statement of Profit or Loss and Other Comprehensive Income

for the year ended 30 June 2022

	Note	Consolidated	
		2022 \$'000	2021 \$'000 Restated ⁽²⁾
Revenue from services		192,294	183,605
Employee benefits expense ⁽¹⁾		(66,877)	(55,765)
Clinician fees		(33,621)	(32,673)
Raw materials and consumables used		(19,787)	(19,893)
IT and communications expense		(4,464)	(4,179)
Depreciation expense	2.4,2.5	(12,354)	(10,703)
Amortisation expense	2.6	(2,434)	(1,854)
Property expense		(5,525)	(3,820)
Marketing and advertising expense		(6,434)	(6,387)
Professional and other fees		(7,509)	(3,814)
Other expenses		(4,920)	(5,866)
Operating profit		28,369	38,651
Net finance costs	4.4	(2,147)	(2,451)
Profit before tax		26,222	36,200
Income tax expense	1.5	(7,720)	(10,513)
Net profit after tax for the year		18,502	25,687
Other comprehensive income/(loss)			
Items that may be reclassified subsequently to profit or loss:			
Exchange difference on translation of foreign operations		(194)	(233)
Other comprehensive income/(loss) for the year, net of tax		(194)	(233)
Total comprehensive income for the year		18,308	25,454
Profit attributable to:			
Owners of the Company		18,406	25,330
Non-controlling interests		96	357
Profit for the year		18,502	25,687
Total comprehensive income attributable to:			
Owners of the Company		18,212	25,097
Non-controlling interests		96	357
Total comprehensive income for the year		18,308	25,454
Earnings per share			
Basic earnings per share (cents)	1.4	4.7	6.5
Diluted earnings per share (cents)	1.4	4.7	6.5

⁽¹⁾ FY2021 Includes JobKeeper Subsidy impact of \$5.06m (refer note 1.1).

⁽²⁾ 30 June 2021 has been restated due to the IFRS Interpretations Committee decision in relation to accounting for Software as a Service (refer to note 6.2).

The consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.